Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer

Research output: Contribution to journalArticle

Abstract

Glutamate carboxypeptidase II (GCPII) is a membrane-bound binuclear zinc metallopeptidase with the highest expression levels found in the nervous and prostatic tissue. Throughout the nervous system, glia-bound GCPII is intimately involved in the neuronneuron and neuron-glia signaling via the hydrolysis of N-acetylaspartylglutamate (NAAG), the most abundant mammalian peptidic neurotransmitter. The inhibition of the GCPII-controlled NAAG catabolism has been shown to attenuate neurotoxicity associated with enhanced glutamate transmission and GCPII-specific inhibitors demonstrate efficacy in multiple preclinical models including traumatic brain injury, stroke, neuropathic and inflammatory pain, amyotrophic lateral sclerosis, and schizophrenia. The second major area of pharmacological interventions targeting GCPII focuses on prostate carcinoma; GCPII expression levels are highly increased in androgenindependent and metastatic disease. Consequently, the enzyme serves as a potential target for imaging and therapy. This review offers a summary of GCPII structure, physiological functions in healthy tissues, and its association with various pathologies. The review also outlines the development of GCPII-specific small-molecule compounds and their use in preclinical and clinical settings.

Original languageEnglish (US)
Pages (from-to)856-870
Number of pages15
JournalCurrent Medicinal Chemistry
Volume19
Issue number6
DOIs
StatePublished - Feb 2012

Fingerprint

Glutamate Carboxypeptidase II
Nervous System Diseases
Prostatic Neoplasms
Therapeutics
Neuroglia
Tissue
Nerve Tissue
Amyotrophic Lateral Sclerosis
Neurology
Metalloproteases
Neuralgia
Pathology
Nervous System
Neurons
Neurotransmitter Agents
Zinc
Prostate
Glutamic Acid
Hydrolysis
Brain

Keywords

  • Glutamate excitotoxicity
  • Metalloprotease
  • N-acetylaspartylglutamate
  • Prostate cancer
  • Prostate-specific membrane antigen

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

@article{87f45dca4bd34a4babde4b4230f98556,
title = "Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer",
abstract = "Glutamate carboxypeptidase II (GCPII) is a membrane-bound binuclear zinc metallopeptidase with the highest expression levels found in the nervous and prostatic tissue. Throughout the nervous system, glia-bound GCPII is intimately involved in the neuronneuron and neuron-glia signaling via the hydrolysis of N-acetylaspartylglutamate (NAAG), the most abundant mammalian peptidic neurotransmitter. The inhibition of the GCPII-controlled NAAG catabolism has been shown to attenuate neurotoxicity associated with enhanced glutamate transmission and GCPII-specific inhibitors demonstrate efficacy in multiple preclinical models including traumatic brain injury, stroke, neuropathic and inflammatory pain, amyotrophic lateral sclerosis, and schizophrenia. The second major area of pharmacological interventions targeting GCPII focuses on prostate carcinoma; GCPII expression levels are highly increased in androgenindependent and metastatic disease. Consequently, the enzyme serves as a potential target for imaging and therapy. This review offers a summary of GCPII structure, physiological functions in healthy tissues, and its association with various pathologies. The review also outlines the development of GCPII-specific small-molecule compounds and their use in preclinical and clinical settings.",
keywords = "Glutamate excitotoxicity, Metalloprotease, N-acetylaspartylglutamate, Prostate cancer, Prostate-specific membrane antigen",
author = "C. Bařinka and Camilo Rojas and Barbara Slusher and Pomper, {Martin Gilbert}",
year = "2012",
month = "2",
doi = "10.2174/092986712799034888",
language = "English (US)",
volume = "19",
pages = "856--870",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer

AU - Bařinka, C.

AU - Rojas, Camilo

AU - Slusher, Barbara

AU - Pomper, Martin Gilbert

PY - 2012/2

Y1 - 2012/2

N2 - Glutamate carboxypeptidase II (GCPII) is a membrane-bound binuclear zinc metallopeptidase with the highest expression levels found in the nervous and prostatic tissue. Throughout the nervous system, glia-bound GCPII is intimately involved in the neuronneuron and neuron-glia signaling via the hydrolysis of N-acetylaspartylglutamate (NAAG), the most abundant mammalian peptidic neurotransmitter. The inhibition of the GCPII-controlled NAAG catabolism has been shown to attenuate neurotoxicity associated with enhanced glutamate transmission and GCPII-specific inhibitors demonstrate efficacy in multiple preclinical models including traumatic brain injury, stroke, neuropathic and inflammatory pain, amyotrophic lateral sclerosis, and schizophrenia. The second major area of pharmacological interventions targeting GCPII focuses on prostate carcinoma; GCPII expression levels are highly increased in androgenindependent and metastatic disease. Consequently, the enzyme serves as a potential target for imaging and therapy. This review offers a summary of GCPII structure, physiological functions in healthy tissues, and its association with various pathologies. The review also outlines the development of GCPII-specific small-molecule compounds and their use in preclinical and clinical settings.

AB - Glutamate carboxypeptidase II (GCPII) is a membrane-bound binuclear zinc metallopeptidase with the highest expression levels found in the nervous and prostatic tissue. Throughout the nervous system, glia-bound GCPII is intimately involved in the neuronneuron and neuron-glia signaling via the hydrolysis of N-acetylaspartylglutamate (NAAG), the most abundant mammalian peptidic neurotransmitter. The inhibition of the GCPII-controlled NAAG catabolism has been shown to attenuate neurotoxicity associated with enhanced glutamate transmission and GCPII-specific inhibitors demonstrate efficacy in multiple preclinical models including traumatic brain injury, stroke, neuropathic and inflammatory pain, amyotrophic lateral sclerosis, and schizophrenia. The second major area of pharmacological interventions targeting GCPII focuses on prostate carcinoma; GCPII expression levels are highly increased in androgenindependent and metastatic disease. Consequently, the enzyme serves as a potential target for imaging and therapy. This review offers a summary of GCPII structure, physiological functions in healthy tissues, and its association with various pathologies. The review also outlines the development of GCPII-specific small-molecule compounds and their use in preclinical and clinical settings.

KW - Glutamate excitotoxicity

KW - Metalloprotease

KW - N-acetylaspartylglutamate

KW - Prostate cancer

KW - Prostate-specific membrane antigen

UR - http://www.scopus.com/inward/record.url?scp=84857589525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857589525&partnerID=8YFLogxK

U2 - 10.2174/092986712799034888

DO - 10.2174/092986712799034888

M3 - Article

C2 - 22214450

AN - SCOPUS:84857589525

VL - 19

SP - 856

EP - 870

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 6

ER -